Launoy Guy, Bossard Nadine, Castro Clara, Manfredi Sylvain
aU1086 INSERM-UCBNCancers and Preventions, Centre François Baclesse, Caen bService de Biostatistique, Hospices Civils de Lyon cUniversité de Lyon, Lyon dUniversité Lyon 1 eCNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne fRegistre Bourguignon des Cancers Digestifs, CHU de Dijon; INSERM U 866; Université de Bourgogne, France gNorth Region Cancer Registry of Portugal (RORENO), Portuguese Oncology Institute of Porto, Porto, Portugal.
Eur J Cancer Prev. 2017 Jan;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study:S24-S31. doi: 10.1097/CEJ.0000000000000308.
Esophageal cancer represents a major clinical challenge because of its poor prognosis. The aim of the SUDCAN collaborative study was to compare the net survival from esophageal cancer between six European Latin countries (Belgium, France, Italy, Portugal, Spain, and Switzerland) and report the trends in net survival and the dynamics of excess mortality rates (EMRs) up to 5 years after diagnosis. The data were extracted from the EUROCARE-5 database. First, net survival was studied over the period 2000-2004 using the Pohar-Perme estimator. For trend analyses, the study period was specific to each country. The results were reported from 1992 to 2004 in France, Italy, Spain, and Switzerland and from 2000 to 2004 in Belgium and Portugal. These trend analyses were carried out using a flexible excess rate modeling strategy. There were some differences between countries in age-standardized net survival (2000-2004). The 5-year net survival ranged between 9 (Spain) and 21% (Belgium). The small increase in net survival from 1992 and 2004 was mostly observed at ages 55 and 65, but was less marked at age 75. There was a slight decrease in EMR between 1992 and 2004 until ∼24 months after diagnosis. Beyond this period, the decrease in the EMR was moderate and the same in all countries irrespective of the year of diagnosis. Some improvement in the 5-year net survival was observed in all countries limited to the 24 months after diagnosis. However, survival differences between countries persisted. Further improvement is expected from innovative treatments.
由于预后较差，食管癌是一项重大的临床挑战。SUDCAN合作研究的目的是比较六个欧洲拉丁国家（比利时、法国、意大利、葡萄牙、西班牙和瑞士）食管癌的净生存率，并报告净生存率的趋势以及诊断后长达5年的超额死亡率（EMR）动态。数据从EUROCARE - 5数据库中提取。首先，使用Pohar - Perme估计量研究了2000 - 2004年期间的净生存率。对于趋势分析，研究期间因国家而异。法国、意大利、西班牙和瑞士报告了1992年至2004年的结果，比利时和葡萄牙报告了2000年至2004年的结果。这些趋势分析采用了灵活的超额率建模策略。各国年龄标准化净生存率（2000 - 2004年）存在一些差异。5年净生存率在9%（西班牙）至21%（比利时）之间。1992年至2004年净生存率的小幅上升主要出现在55岁和65岁年龄段，但在75岁时不太明显。1992年至2004年，直到诊断后约24个月，EMR略有下降。在此之后，EMR下降幅度适中，所有国家均相同，与诊断年份无关。所有国家在诊断后的24个月内5年净生存率都有一定改善。然而，各国之间的生存差异仍然存在。预计创新疗法将带来进一步改善。
